# Protagonist Therapeutics Type: Company (PTGX) Source: GetYourBrief — https://getyourbrief.com/entity/protagonist-therapeutics Canonical HTML page: https://getyourbrief.com/entity/protagonist-therapeutics ## Timeline - **2026-Q4**: Data Readout — Anticipated top-line data from the Phase 3 VERIFY clinical trial. - **2026-03-18**: Q4 Earnings — Scheduled announcement of quarterly financial results and pipeline update. - **2026-03-18**: Quarterly Earnings — Expected announcement of financial results and pipeline updates for PTGX and OEZVY. - **2026-03-18**: Quarterly Earnings Release — Official financial results and conference calls scheduled for both companies. - **2026-03-17**: Pre-Earnings Market Activity — Both OEZVY and PTGX see increased trading volume ahead of Wednesday reports. - **2026-02-26**: Takeda Deal Restructuring — Protagonist opts out of profit-sharing for Rusfertide in exchange for $400M cash. - **2026-02-25**: Institutional Exit Revealed — 13F filings reveal a $170 million divestment by a major institutional fund. - **2026-02-25**: Institutional Exit — SEC filings reveal a $170 million position liquidation by a major fund. - **2026-01-20**: 120% Gain Milestone — PTGX stock reaches a 120% gain milestone from its 52-week low. - **2025-11-01**: J&J Partnership Milestone — Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech. - **2025-Q4**: 120% Rally — Stock price reaches a 12-month peak following sustained clinical momentum. - **2025-Q4**: JNJ-2113 Phase 3 Progress — Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials. - **2025-06-15**: Phase 3 Data Release — Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally. - **2025-01-10**: VERIFY Enrollment — Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera. - **2025-Q1**: J&J Partnership Expansion — Johnson & Johnson expands the scope of the oral peptide collaboration. ## Recent coverage (8 stories, network-wide) ### PTGX's 2 Shot-on-Goal Strategy: ICOTYDE Approved, Rusfertide Priority Review, $620M Cash 2026-06-14 01:25:38 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2 Protagonist Therapeutics has transitioned from binary clinical risk to execution risk, with ICOTYDE's FDA approval and rusfertide's Priority Review. Backed by $620 million in cash, the company's validated peptide platform and royalty-based revenue model offer a compelling biotech investment thesis. Full story: https://getbiobrief.com/story/ptgx-2-shots-on-goal-icotyde-approved-rusfertide-priority-review ### How Protagonist’s $620M Cash Runway Through 2028 Supports 2 Peptide Drug Launches 2026-06-14 01:25:03 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2 Protagonist Therapeutics' shift to a royalty-driven, capital-light model ensures sustained funding for two near-term peptide drug launches. With over $620 million in cash, the company is poised to deliver new treatment options while minimizing financial risk. Full story: https://gethealthbrief.com/story/protagonist-therapeutics-620m-cash-runway-2-drug-launches-health ### Verbund and Protagonist Therapeutics Set for Key Mid-Week Earnings Reports 2026-03-17 07:34:46 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Austrian utility giant Verbund and biotech firm Protagonist Therapeutics are scheduled to release quarterly results this Wednesday. Investors will be scrutinizing Verbund's hydropower margins and Protagonist's cash position following its recent $400 million deal with Takeda. Full story: https://getfinancebrief.com/story/verbund-protagonist-earnings-preview-march-2026 ### Protagonist Therapeutics Braces for Q1 Earnings Amid Pipeline Milestones 2026-03-17 07:33:39 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity. Full story: https://getbiobrief.com/story/protagonist-therapeutics-verbund-earnings-preview-2026 ### Protagonist Therapeutics Eyes Pivotal Q4 Results Amid Oral Peptide Expansion 2026-03-17 07:33:05 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors. Full story: https://gethealthbrief.com/story/protagonist-therapeutics-q4-earnings-preview-2026 ### Protagonist Therapeutics Surges 120% as Major Fund Discloses $170M Exit 2026-02-25 21:54:31 · Sector: startups · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones. Full story: https://getstartupbrief.com/story/protagonist-therapeutics-120-percent-surge-170-million-exit ### Protagonist Stock Surges 120% as Major Fund Reveals $170 Million Exit 2026-02-25 21:49:49 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector. Full story: https://getfinancebrief.com/story/protagonist-therapeutics-stock-surge-institutional-exit ### Protagonist Therapeutics Surges 120% as Major Fund Trims $170M Stake 2026-02-25 21:44:08 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2 Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer. Full story: https://getbiobrief.com/story/protagonist-therapeutics-stock-surge-institutional-exit --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.